Wide Ranks

CNTB

Connect Biopharma Holdings Limi

1.03

Top Statistics
Market Cap 56 M Forward PE inf Revenue Growth 0.00 %
Current Ratio 12.04 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -88.66 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 2.12 Enterprise / Revenue -2.20 Price To Sales Trailing12 Months 2.36
Profitability
Profit Margins -88.66 % Operating Margins 24.64 %
Balance Sheet
Total Cash 110 M Total Cash Per Share 2.00 Total Debt 325000
Total Debt To Equity 0.2940 Current Ratio 12.04 Book Value Per Share 2.00
All Measures
Short Ratio 241.00 % Message Board Id finmb_706016439 Fax 858 614 7007
Shares Short Prior Month 45468 Return On Equity -0.1792 City San Diego
Uuid f1aecc10-79bf-31c7-a21a-8af27158e95e Previous Close 0.9880 First Trade Date Epoch Utc 1 B
Book Value 2.00 Beta -0.3080 Total Debt 325000
Volume 39163 Price To Book 0.5153 Fifty Two Week Low 0.6780
Total Cash Per Share 2.00 Total Revenue 24 M Shares Short Previous Month Date 1 B
Target Median Price 7.00 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins 24.64 % Target Mean Price 7.00 Net Income To Common -21380000
Short Percent Of Float 0.0020 Implied Shares Outstanding 55 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 24610 Average Volume10days 24610
Total Cash 110 M Next Fiscal Year End 1 B Revenue Per Share 0.4380
Held Percent Insiders 0.4116 Ebitda Margins -103.46 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 0.9880
Target Low Price 6.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.20
Open 0.9700 Free Cashflow -17080772 State CA
Dividend Yield 0.00 % Return On Assets -0.1213 Time Zone Short Name EST
Trailing Eps -0.3900 Day Low 0.9350 Address1 12265 El Camino Real
Shares Outstanding 55 M Price Hint 4 Target High Price 8.00
Website https://www.connectbiopharm.com 52 Week Change -0.1043 Average Volume 30670
Forward Eps -0.2000 Recommendation Key none Quick Ratio 1182.50 %
Is_sp_500 False Regular Market Day High 1.05 Profit Margins -88.66 %
Debt To Equity 0.2940 Fifty Two Week High 2.66 Day High 1.05
Shares Short 61794 Regular Market Open 0.9700 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue -2.20 Revenue Growth 0.00 %
Shares Percent Shares Out 0.0011 Operating Cashflow -24749000 Currency USD
Time Zone Full Name America/New_York Market Cap 56 M Is_nasdaq_100 False
Zip 92130 Quote Type EQUITY Industry Biotechnology
Long Name Connect Biopharma Holdings Limited Regular Market Day Low 0.9350 Held Percent Institutions 0.4443
Current Price 1.03 Address2 Suite 350 Enterprise To Ebitda 2.12
Financial Currency USD Current Ratio 12.04 Gross Margins 100.00 %
Industry Disp Biotechnology Number Of Analyst Opinions 2 Country United States
Float Shares 14 M Two Hundred Day Average 1.35 Enterprise Value -53004348
Price To Sales Trailing12 Months 2.36 Forward PE inf Regular Market Volume 39163
Ebitda -24951000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases.

The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.

Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease.

The company was founded in 2012 and is based in San Diego, California.